Literature DB >> 22291189

Regulatory dendritic cells pulsed with carbonic anhydrase I protect mice from colitis induced by CD4+CD25- T cells.

Hirofumi Yamanishi1, Hidehiro Murakami, Yoshiou Ikeda, Masanori Abe, Teru Kumagi, Yoichi Hiasa, Bunzo Matsuura, Morikazu Onji.   

Abstract

Inflammatory bowel disease (IBD), which is characterized by a dysregulated intestinal immune response, is postulated to be controlled by intestinal self-antigens and bacterial Ags. Fecal extracts called cecal bacterial Ag (CBA) have been implicated in the pathogenesis of IBD. In this study, we identified a major protein of CBA related to the pathogenesis of IBD and established a therapeutic approach using Ag-pulsed regulatory dendritic cells (Reg-DCs). Using two-dimensional gel electrophoresis and MALDI-TOF mass spectrometry, carbonic anhydrase I (CA I) was identified as a major protein of CBA. Next, we induced colitis by transfer of CD4(+)CD25(-) T cells obtained from BALB/c mice into SCID mice. Mice were treated with CBA- or CA I-pulsed Reg-DCs (Reg-DCs(CBA) or Reg-DCs(CA1)), which expressed CD200 receptor 3 and produced high levels of IL-10. Treatment with Reg-DCs(CBA) and Reg-DCs(CA1) ameliorated colitis. This effect was shown to be Ag-specific based on no clinical response of irrelevant Ag (keyhole limpet hemocyanin)-pulsed Reg-DCs. Foxp3 mRNA expression was higher but RORγt mRNA expression was lower in the mesenteric lymph nodes (MLNs) of the Reg-DCs(CA1)-treated mice compared with those in the MLNs of control mice. In the MLNs, Reg-DCs(CA1)-treated mice had higher mRNA expression of IL-10 and TGF-β1 and lower IL-17 mRNA expression and protein production compared with those of control mice. In addition, Reg-DCs(CBA)-treated mice had higher Foxp3(+)CD4(+)CD25(+) and IL-10-producing regulatory T cell frequencies in MLNs. In conclusion, Reg-DCs(CA1) protected progression of colitis induced by CD4(+)CD25(-) T cell transfer in an Ag-specific manner by inducing the differentiation of regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22291189     DOI: 10.4049/jimmunol.1100559

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

Authors:  Ross John Porter; Caroline Andrews; Daniel Paul Brice; Scott Kenneth Durum; Mairi Hall McLean
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

Review 2.  Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?

Authors:  Ana I Flores; Gonzalo J Gómez-Gómez; Ángeles Masedo-González; M Pilar Martínez-Montiel
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

3.  Heligmosomoides polygyrus bakeri infection activates colonic Foxp3+ T cells enhancing their capacity to prevent colitis.

Authors:  Long Hang; Arthur M Blum; Tommy Setiawan; Joseph P Urban; Korynn M Stoyanoff; Joel V Weinstock
Journal:  J Immunol       Date:  2013-07-12       Impact factor: 5.422

4.  Heligmosomoides polygyrus bakeri induces tolerogenic dendritic cells that block colitis and prevent antigen-specific gut T cell responses.

Authors:  Arthur M Blum; Long Hang; Tommy Setiawan; Joseph P Urban; Korynn M Stoyanoff; John Leung; Joel V Weinstock
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

Review 5.  From genetics of inflammatory bowel disease towards mechanistic insights.

Authors:  Daniel B Graham; Ramnik J Xavier
Journal:  Trends Immunol       Date:  2013-04-30       Impact factor: 16.687

6.  Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer.

Authors:  Mingzhen Zhang; Emilie Viennois; Meena Prasad; Yunchen Zhang; Lixin Wang; Zhan Zhang; Moon Kwon Han; Bo Xiao; Changlong Xu; Shanthi Srinivasan; Didier Merlin
Journal:  Biomaterials       Date:  2016-06-09       Impact factor: 12.479

7.  Endotoxic shock-expanded murine CD11c low CD45RB + regulatory dendritic cells modulate inflammatory T cell responses through multiple mechanisms.

Authors:  Xiaoqian Wang; Qingyang Wang; Xueying Zhang; Yajing Li; Jingyang Wang; Chunmei Hou; Juan Chen; Beifen Shen; Yanchun Shi; Jiyan Zhang
Journal:  Sci Rep       Date:  2015-05-29       Impact factor: 4.379

Review 8.  Novel cell-based therapies in inflammatory bowel diseases: the established concept, promising results.

Authors:  Nikoo Hossein-Khannazer; Shukoofeh Torabi; Ramin Hosseinzadeh; Shabnam Shahrokh; Hamid Asadzadeh Aghdaei; Arash Memarnejadian; Nadir Kadri; Massoud Vosough
Journal:  Hum Cell       Date:  2021-05-31       Impact factor: 4.174

9.  Transgenic mice over-expressing carbonic anhydrase I showed aggravated joint inflammation and tissue destruction.

Authors:  Yabing Zheng; Lin Wang; Wei Zhang; Hengwei Xu; Xiaotian Chang
Journal:  BMC Musculoskelet Disord       Date:  2012-12-20       Impact factor: 2.362

10.  Lost therapeutic potential of monocyte-derived dendritic cells through lost tissue homing: stable restoration of gut specificity with retinoic acid.

Authors:  D Bernardo; E R Mann; H O Al-Hassi; N R English; R Man; G H Lee; E Ronde; J Landy; S T C Peake; A L Hart; S C Knight
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.